Floris C. Loeff

R&d
Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: March 29, 2026

Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study.

Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study.

Journal: Clinical and translational science

Published: February 18, 2026

Therapeutic Drug Monitoring of Rituximab to Predict Early B-Cell Repopulation in Children With Inflammatory Diseases.

Therapeutic Drug Monitoring of Rituximab to Predict Early B-Cell Repopulation in Children With Inflammatory Diseases.

Journal: The Journal of rheumatology

Published: February 09, 2026

Clinical implications of natalizumab Fab-arm exchange in patients with multiple sclerosis.

Clinical implications of natalizumab Fab-arm exchange in patients with multiple sclerosis.

Journal: Frontiers in immunology

Published: January 26, 2026

The Association Between Serum Drug Concentration and a Flare in Rheumatoid Arthritis Patients Tapering TNF Inhibitors.

The Association Between Serum Drug Concentration and a Flare in Rheumatoid Arthritis Patients Tapering TNF Inhibitors.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: August 11, 2025

Quality Assessment of Therapeutic Drug Monitoring Assays of Therapeutic Antibodies Across Europe: An Update.

Quality Assessment of Therapeutic Drug Monitoring Assays of Therapeutic Antibodies Across Europe: An Update.

Journal: Basic & clinical pharmacology & toxicology

Published: May 23, 2025

Proceedings of the 15th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals.

Proceedings of the 15th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals.

Journal: mAbs

Published: April 04, 2025

Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis.

Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: December 31, 2024

Belimumab concentrations and immunogenicity in relation to drug effectiveness and safety in SLE within a Swedish real-world setting.

Belimumab concentrations and immunogenicity in relation to drug effectiveness and safety in SLE within a Swedish real-world setting.

Journal: Rheumatology (Oxford, England)

Published: December 16, 2024

Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration.

Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration.

Journal: Multiple sclerosis and related disorders

Published: April 11, 2024

Patient-perspective and feasibility of home finger-prick testing to complement and facilitate large-scale research in rheumatology.

Patient-perspective and feasibility of home finger-prick testing to complement and facilitate large-scale research in rheumatology.

Journal: RMD open

Published: November 22, 2023

Belimumab concentration measurements using a homologous anti-idiotype immunoassay.

Belimumab concentration measurements using a homologous anti-idiotype immunoassay.

Journal: Journal of immunological methods

Published: November 08, 2023

Showing 1-12 of 38

Last Updated: 09/26/2026